Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioNTech SE BNTX

Healthcare Biotechnology
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.


NDAQ:BNTX - Post by User

BioNTech SE
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(291)
•••
Post by whytestockson Sep 18, 2024 7:02pm
36 Views
Post# 36230053

Neutral Recommendation Issued On BNTX By UBS

Neutral Recommendation Issued On BNTX By UBS
Breaking News: $BNTX Neutral Recommendation Issued On BNTX By UBS2024-09-18 08:30:04 ET UBS analyst issues NEUTRAL recommendation for BNTX on September 18, 2024 07:04AM ET. The previous analyst recommendation was Neutral. BNTX was trading at $124.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...BNTX - Neutral Recommendation Issued On BNTX By UBS

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities